1 Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical College, Wenzhou; and Department of Neurosurgery, Fu Xing Hospital, Capital University of Medical Science, Beijing, People’s Republic of China
The aim of this study was to observe long-term clinical outcomes in a group of patients treated with bromocriptine for invasive giant prolactinomas involving the cavernous sinus.
Data from 20 patients with invasive giant prolactinomas at the authors’ institutions between July 1997 and June 2004 were retrospectively reviewed. The criteria to qualify for study participation included: 1) tumor diameter greater than 4 cm, invading the cavernous sinus to an extent corresponding to Grade III or IV in the classification scheme of Knosp and colleagues; 2) serum prolactin (PRL) level greater than 200 ng/ml; and 3) clinical signs of hyperprolactinemia and mass effect. Among the 20 patients who met the criteria, six had undergone unsuccessful transcranial or transsphenoidal microsurgery prior to bromocriptine treatment and 14 patients received bromocriptine as the primary treatment. Eleven of the 20 patients underwent adjuvant radiotherapy.
After a mean follow-up period of 37.3 months, the clinical symptoms in all patients improved by different degrees. Tumor volume on magnetic resonance images was decreased by a mean of 93.3%. In 11 patients, the tumor had almost completely disappeared; in the other nine patients, residual tumor invaded the cavernous sinus. Visual symptoms improved in 13 of the patients who had presented with visual loss. Eight patients had normal PRL levels. The postoperative PRL level was more than 200 ng/ml in seven patients. During the course of drug administration, cerebrospinal fluid leakage occurred in one patient, who subsequently underwent transsphenoidal surgery. No case of apoplexy occurred during bromocriptine treatment.
Dopamine agonist medications are effective as a first-line therapy for invasive giant prolactinomas, because they can significantly shrink tumor volume and control the PRL level. Tumor mass vanishes in some patients after bromocriptine treatment; in other patients with localized residual tumor, stereotactic radiosurgery is a viable option so that unnecessary surgery can be avoided. The application of radiotherapy does not reliably shrink tumor volume.
Abbreviations used in this paper: CSF = cerebrospinal fluid; MR = magnetic resonance; PRL = prolactin.
Address reprint requests to: Zhe Bao Wu, M.D., Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, People’s Republic of China. email:
ColaoADi SarnoALandiMLScavuzzoFCappabiancaPPivonelloR: Macroprolactinoma shrinkage during cabergoline treatment is greater in naïve patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab85:2247–22522000
CouldwellWTWeissMHRabbCLiuJKApfelbaumRIFukushimaT: Variations on the standard transsphenoidal approach to the sellar region, with emphasis on the extended approaches and parasellar approaches: surgical experience in 105 cases. Neurosurgery55:539–5502004
Di SarnoALandiMLCappabiancaPDi SalleFRossiFWPivonelloR: Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab86:5256–52612001
HofleGGasserRMohsenipourIFinkenstedtG: Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study. Exp Clin Endocrinol Diabetes106:211–2161998
InoueHKKohgaHHiratoMSasakiTIshiharaJShibazakiT: Pituitary adenomas treated by microsurgery with or without Gamma Knife surgery: experience in 122 cases. Stereotact Funct Neurosurg72 :Suppl 1125–1311999
MolitchMEEltonRLBlackwellRECaldwellBChangRJJaffeR: Bromocriptine as primary therapy for prolactinsecreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab60:698–7051985
OzgenTOruckaptanHHOzcanOEAcikgozB: Prolactin secreting pituitary adenomas: analysis of 429 surgically treated patients, effect of adjuvant treatment modalities and review of the literature. Acta Neurochir (Wien)141:1287–12941999
TindallGTKovacsKHarvathEThornerMO: Human prolactinproducing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab55:1178–11831982